These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32942096)

  • 21. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes: an overview.
    Jansen G; Scheper RJ; Dijkmans BA
    Scand J Rheumatol; 2003; 32(6):325-36. PubMed ID: 15080263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tocilizumab in the treatment of adult rheumatoid arthritis.
    Sanmartí R; Ruiz-Esquide V; Bastida C; Soy D
    Immunotherapy; 2018 Mar; 10(6):447-464. PubMed ID: 29495891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methotrexate pharmacogenetics in rheumatoid arthritis.
    Brinker RR; Ranganathan P
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S33-9. PubMed ID: 21044431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of rheumatoid arthritis by molecular-targeted agents: efficacy and limitations.
    Koike T
    J Orthop Sci; 2015 Nov; 20(6):951-7. PubMed ID: 26404390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.
    Roubille C; Haraoui B
    Semin Arthritis Rheum; 2014 Apr; 43(5):613-26. PubMed ID: 24231065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of the ABCB1 C3435T polymorphism with responsiveness to and toxicity of DMARDs in rheumatoid arthritis : A meta-analysis.
    Lee YH; Bae SC; Song GG
    Z Rheumatol; 2016 Sep; 75(7):707-15. PubMed ID: 26184955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in focal adhesion kinase expression in rats with collagen-induced arthritis and efficacy of intervention with disease modifying anti-rheumatic drugs alone or in combination.
    Gao HY; Luo J; Li XF; Lv Q; Wen HY; Song QZ; Zhao WP; Zhao XC; Zhang TT; Zhang SY; Zhi JM
    Int J Clin Exp Pathol; 2015; 8(12):15573-81. PubMed ID: 26884826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of methotrexate in combination with other non-biologic disease-modifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritis.
    Castrejón I; Gibson KA; Pincus T
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S20-8. PubMed ID: 24219037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies toward rheumatoid arthritis therapy; the old and the new.
    Abbasi M; Mousavi MJ; Jamalzehi S; Alimohammadi R; Bezvan MH; Mohammadi H; Aslani S
    J Cell Physiol; 2019 Jul; 234(7):10018-10031. PubMed ID: 30536757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
    Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
    Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulatory effects of inflammation and therapy on GDF-5 expression in rheumatoid arthritis synovium.
    Bramlage CP; Kaps C; Ungethüm U; Bramlage P; Koziolek M; Wessels J; Krenn V; Pruss A; Müller GA; Strutz F; Burmester GR; Häupl T
    Scand J Rheumatol; 2008; 37(6):401-9. PubMed ID: 18830904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update.
    Zhu H; Deng FY; Mo XB; Qiu YH; Lei SF
    Pharmacogenomics; 2014 Mar; 15(4):551-66. PubMed ID: 24624921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
    Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
    Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of methotrexate and low-dose prednisolone on adiponectine levels and insulin resistance in patients with rheumatoid arthritis naïve to disease-modifying antirheumatic drugs.
    Yaşar Bilge NŞ; Kaşifoğlu N; Kaşifoğlu T; Şahin F; Gönüllü E; Korkmaz C
    Int J Rheum Dis; 2016 Jul; 19(7):665-71. PubMed ID: 26222244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [ Bone and cartilage destruction in RA and its intervention. Disease-modifying antirheumatic drugs].
    Ichikawa N; Yamanaka H
    Clin Calcium; 2012 Feb; 22(2):215-21. PubMed ID: 22298075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.